Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 2/20 | 0.31 |
| ▸ | HEXB | P07686 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914615 | 0.82 | LMNA (0.41) | KDM4ELMNAALDH1A1CA12CA1 | |
| SCHEMBL27547634 | 0.80 | CA12 (0.33) | KDM4ELMNAALDH1A1CA12CA1 | |
| SCHEMBL721411 | 0.79 | TP53 (0.36) | ALDH1A1MAPTTP53HEXAHEXB | |
| SCHEMBL195576 | 0.76 | LMNA (0.36) | KDM4ELMNAALDH1A1CA12CA1 | |
| SCHEMBL263267 | 0.75 | NOS3 (0.34) | ALDH1A1TSHRRAPGEF4 | |
| SCHEMBL6286439 | 0.75 | TP53 (0.36) | ALDH1A1MAPTTP53HEXAHEXB | |
| SCHEMBL9139369 | 0.74 | TP53 (0.41) | TP53TSHRRAPGEF4 | |
| SCHEMBL510173 | 0.74 | ALDH1A1 (0.41) | KDM4EALDH1A1CA1CA2CA9 | |
| SCHEMBL6870040 | 0.73 | CA1 (0.35) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL4648563 | 0.70 | KDM4E (0.33) | KDM4ELMNAALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597198-B1 | METHOD FOR STABILISING DISPERSIONS | WACKER CHEMIE AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1473296-B1 | Organofunctional surface modified metal oxides | WACKER CHEMIE AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1473296-A1 | Organofunctional surface modified metal oxides | Wacker-Chemie GmbH (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040082567-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-4895987-A | Phosphonite-and phosphonite-promoted ruthenium - cobalt catalysts for the dealkoxyhydroxymethylation of acetals to form glycol ethers | SUN REFINING AND MARKETING COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0312659-A1 | Phosphonite-and phosphinite-promoted ruthenium - cobalt catalysts for the dealkoxyhydroxymethylation of acetals to form glycol ethers | Sun Refining and Marketing Company (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082567-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | KDM4E 1780/4885LMNA 469/4885ALDH1A1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.